Assoc Prof Dipti Talaulikar

A/Prof Dipti Talaulikar is an experienced clinical haematologist at Icon Cancer Centre Canberra. In 2003, she established her haematology career in Canberra as an advanced trainee haematology registrar at Canberra Hospital whilst completing post-graduate studies at the Australian National University (ANU). A/Prof Talaulikar has completed a graduate certificate in higher education and PhD investigating occult bone marrow involvement in Diffuse Large B-cell lymphoma. She is a senior fellow of the ANU Higher Education Academy (HEA).

A/Prof Talaulikar maintains a strong interest in medical leadership, research and clinical trials in both her private practice and role as senior staff specialist at Canberra Hospital. She has been principal investigator and co-investigator of several lymphoma, leukaemia and myeloma trials. She is an Associate Professor (Level D) of the College of Medicine, Biology and Environment at ANU and is actively involved in the academic supervision and teaching of emerging medical professionals. She is a member of several leading cancer trial and research groups including the Australasian Leukaemia & Lymphoma Group (ALLG), Australian Lymphoma Alliance, American Society of Haematology (ASH) and Haematology Society of Australia and New Zealand (HSANZ). She is also a member of the Medical & Scientific Advisory Group (MSAG) of Myeloma Australia & a steering committee member of the Lymphoma and Related Diseases Registry (LaRDR).

A/Prof Talaulikar has published several clinical research articles and practice guidelines in leading publications, including the Journal of Internal Medicine and British Journal of Haematology. She is also a regular invited speaker at national and international haematology conferences. A/Prof Talaulikar is a fellow of the Royal Australasian College of Physicians (FRACP) and Royal College of Pathologists of Australasia (FRCPA). Her clinical experience covers a broad range of malignant blood disorders with a special interest in leukaemia, myeloma, lymphoma and myeloproliferative neoplasms.